glp-1 obesity drug news october 2025 today How Supply and Demand for Weight Loss Drugs is Playing Out in 2026 World Health Leaders | FDA

FDA has approved dipeptidyl peptidase-4 (DPP-IV) resistant long-acting GLP-1s as injectable drugs for treating patients with type 2 diabetes

A GLP-1 plateau around month 9 isn't failure it's predictable biology

A qualitative sub-study of the trial by Whicher and colleagues 144 over 17 patients with overweight or obesity and schizophrenia-spectrum disorders found that most of the interviewees and their clinicians had had positive experiences regarding GLP-1RA administrations

It is this dual dysfunction that GLP-1 drugs are designed to address

Roger S

but can be obtained by a physician for patients with refractory gastroparesis though the Investigational New Drug (IND) application program at the FDA